Company intelligence / Profile preview

ABYOLO AG

Unterägeri, Zug, Switzerland

Ownership: Private
Development stage: Preclinical

Overview

ABYOLO AG is an active Swiss-based global biosimilar company focused on making biological medicines accessible and affordable worldwide. The company leverages cutting-edge technologies—including AI and automation—to streamline the development and production of high-quality biosimilars. Its mission centers on bridging healthcare gaps through innovation and operational agility. While specific clinical results or product launches are not publicly detailed, the company's positioning suggests late-stage or commercial readiness for multiple products targeting key therapeutic areas addressed by reference biologics.

Therapeutic areas: Other
Modalities: Biosimilars (biologics)
Industry: Biotech

Beyond the preview

Go deeper on ABYOLO AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABYOLO AG.

Explore the full profile